Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Treasury Shares (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Treasury Shares for 7 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 6.4% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.0 million, a 6.4% increase, with the full-year FY2024 number at $932634.0, up 6.62% from a year prior.
  • Treasury Shares was $1.0 million for Q3 2025 at Pliant Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.3 million in Q1 2025 to a low of $6235.0 in Q1 2022.
  • A 5-year average of $686981.9 and a median of $903691.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: tumbled 93.52% in 2022, then soared 5586.16% in 2023.
  • Pliant Therapeutics' Treasury Shares stood at $37838.0 in 2021, then skyrocketed by 836.97% to $354532.0 in 2022, then surged by 146.73% to $874748.0 in 2023, then rose by 6.62% to $932634.0 in 2024, then rose by 8.51% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Treasury Shares are $1.0 million (Q3 2025), $1.1 million (Q2 2025), and $1.3 million (Q1 2025).